104 related articles for article (PubMed ID: 1672825)
1. Biochemical analysis of the ligand for the neu oncogenic receptor.
Yarden Y; Peles E
Biochemistry; 1991 Apr; 30(14):3543-50. PubMed ID: 1672825
[TBL] [Abstract][Full Text] [Related]
2. Signal transduction by the neu/erbB-2 receptor: a potential target for anti-tumor therapy.
Stancovski I; Peles E; Ben Levy R; Lemprecht R; Kelman Z; Goldman-Michael R; Hurwitz E; Bacus S; Sela M; Yarden Y
J Steroid Biochem Mol Biol; 1992 Sep; 43(1-3):95-103. PubMed ID: 1356018
[TBL] [Abstract][Full Text] [Related]
3. Oncogenic forms of the neu/HER2 tyrosine kinase are permanently coupled to phospholipase C gamma.
Peles E; Levy RB; Or E; Ullrich A; Yarden Y
EMBO J; 1991 Aug; 10(8):2077-86. PubMed ID: 1676673
[TBL] [Abstract][Full Text] [Related]
4. Ligand and p185c-neu density govern receptor interactions and tyrosine kinase activation.
Samanta A; LeVea CM; Dougall WC; Qian X; Greene MI
Proc Natl Acad Sci U S A; 1994 Mar; 91(5):1711-5. PubMed ID: 7907421
[TBL] [Abstract][Full Text] [Related]
5. An oncogenic point mutation confers high affinity ligand binding to the neu receptor. Implications for the generation of site heterogeneity.
Ben-Levy R; Peles E; Goldman-Michael R; Yarden Y
J Biol Chem; 1992 Aug; 267(24):17304-13. PubMed ID: 1355090
[TBL] [Abstract][Full Text] [Related]
6. p185, a product of the neu proto-oncogene, is a receptorlike protein associated with tyrosine kinase activity.
Stern DF; Heffernan PA; Weinberg RA
Mol Cell Biol; 1986 May; 6(5):1729-40. PubMed ID: 2878363
[TBL] [Abstract][Full Text] [Related]
7. Expression of resistance factors (P-glycoprotein, glutathione S-transferase-pi, and topoisomerase II) and their interrelationship to proto-oncogene products in renal cell carcinomas.
Volm M; Kästel M; Mattern J; Efferth T
Cancer; 1993 Jun; 71(12):3981-7. PubMed ID: 8099529
[TBL] [Abstract][Full Text] [Related]
8. Agonistic antibodies stimulate the kinase encoded by the neu protooncogene in living cells but the oncogenic mutant is constitutively active.
Yarden Y
Proc Natl Acad Sci U S A; 1990 Apr; 87(7):2569-73. PubMed ID: 1969636
[TBL] [Abstract][Full Text] [Related]
9. Biochemical comparisons of the normal and oncogenic forms of insect cell-expressed neu tyrosine kinases.
Guy PM; Carraway KL; Cerione RA
J Biol Chem; 1992 Jul; 267(20):13851-6. PubMed ID: 1352772
[TBL] [Abstract][Full Text] [Related]
10. Constitutively activated neu oncoprotein tyrosine kinase interferes with growth factor-induced signals for gene activation.
Lehtola L; Sistonen L; Koskinen P; Lehväslaiho H; Di Renzo MF; Comoglio PM; Alitalo K
J Cell Biochem; 1991 Jan; 45(1):69-81. PubMed ID: 1706346
[TBL] [Abstract][Full Text] [Related]
11. Phosphorylation process induced by epidermal growth factor alters the oncogenic and cellular neu (NGL) gene products.
Kokai Y; Dobashi K; Weiner DB; Myers JN; Nowell PC; Greene MI
Proc Natl Acad Sci U S A; 1988 Aug; 85(15):5389-93. PubMed ID: 2899889
[TBL] [Abstract][Full Text] [Related]
12. Neu and its ligands: from an oncogene to neural factors.
Peles E; Yarden Y
Bioessays; 1993 Dec; 15(12):815-24. PubMed ID: 7908191
[TBL] [Abstract][Full Text] [Related]
13. Activation of the neu tyrosine kinase induces the fos/jun transcription factor complex, the glucose transporter and ornithine decarboxylase.
Sistonen L; Hölttä E; Lehväslaiho H; Lehtola L; Alitalo K
J Cell Biol; 1989 Nov; 109(5):1911-9. PubMed ID: 2572601
[TBL] [Abstract][Full Text] [Related]
14. Bivalence of EGF-like ligands drives the ErbB signaling network.
Tzahar E; Pinkas-Kramarski R; Moyer JD; Klapper LN; Alroy I; Levkowitz G; Shelly M; Henis S; Eisenstein M; Ratzkin BJ; Sela M; Andrews GC; Yarden Y
EMBO J; 1997 Aug; 16(16):4938-50. PubMed ID: 9305636
[TBL] [Abstract][Full Text] [Related]
15. Experimental approaches to hypothetical hormones: detection of a candidate ligand of the neu protooncogene.
Yarden Y; Weinberg RA
Proc Natl Acad Sci U S A; 1989 May; 86(9):3179-83. PubMed ID: 2470093
[TBL] [Abstract][Full Text] [Related]
16. p185c-neu and epidermal growth factor receptor associate into a structure composed of activated kinases.
Quian XL; Decker SJ; Greene MI
Proc Natl Acad Sci U S A; 1992 Feb; 89(4):1330-4. PubMed ID: 1346931
[TBL] [Abstract][Full Text] [Related]
17. Isolation of the neu/HER-2 stimulatory ligand: a 44 kd glycoprotein that induces differentiation of mammary tumor cells.
Peles E; Bacus SS; Koski RA; Lu HS; Wen D; Ogden SG; Levy RB; Yarden Y
Cell; 1992 Apr; 69(1):205-16. PubMed ID: 1348215
[TBL] [Abstract][Full Text] [Related]
18. Regulated coupling of the Neu receptor to phosphatidylinositol 3'-kinase and its release by oncogenic activation.
Peles E; Lamprecht R; Ben-Levy R; Tzahar E; Yarden Y
J Biol Chem; 1992 Jun; 267(17):12266-74. PubMed ID: 1351056
[TBL] [Abstract][Full Text] [Related]
19. The epidermal growth factor receptor and the product of the neu protooncogene are members of a receptor tyrosine phosphorylation cascade.
Connelly PA; Stern DF
Proc Natl Acad Sci U S A; 1990 Aug; 87(16):6054-7. PubMed ID: 1974718
[TBL] [Abstract][Full Text] [Related]
20. Purification and characterization of the neu/erb B2 ligand-growth factor from bovine kidney.
Huang SS; Huang JS
J Biol Chem; 1992 Jun; 267(16):11508-12. PubMed ID: 1350785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
